levofloxacin has been researched along with gallic acid in 3 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (gallic acid) | Trials (gallic acid) | Recent Studies (post-2010) (gallic acid) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 4,793 | 42 | 2,579 |
| Protein | Taxonomy | levofloxacin (IC50) | gallic acid (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 6.6 | |
| Tissue-type plasminogen activator | Homo sapiens (human) | 6.6 | |
| Plasminogen activator inhibitor 1 | Homo sapiens (human) | 6.6 | |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | 6.6 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 4.03 | |
| Matrilysin | Homo sapiens (human) | 4.03 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 4.65 | |
| Alpha-synuclein | Homo sapiens (human) | 4.43 | |
| 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 | Homo sapiens (human) | 4.03 | |
| Polypeptide N-acetylgalactosaminyltransferase 2 | Homo sapiens (human) | 1.37 | |
| Alpha-(1,3)-fucosyltransferase 7 | Homo sapiens (human) | 4.03 | |
| CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 | Homo sapiens (human) | 4.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Adem, S; Aslan, E | 1 |
| Huang, H; Li, P; Liao, K; Liu, B; Liu, C; Su, W; Wang, Y; Zhou, Q | 1 |
3 other study(ies) available for levofloxacin and gallic acid
| Article | Year |
|---|---|
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity.
Topics: Cephalosporins; Coumaric Acids; Flavanones; Folic Acid Antagonists; Gallic Acid; Humans; Kinetics; Levofloxacin; Tetrahydrofolate Dehydrogenase | 2015 |
Pithecellobium clypearia extract enriched in gallic acid and luteolin has antibacterial activity against MRSA and reduces resistance to erythromycin, ceftriaxone sodium and levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Resistance, Bacterial; Drug Synergism; Erythromycin; Fabaceae; Gallic Acid; Levofloxacin; Luteolin; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Plant Extracts; Staphylococcal Infections; Tandem Mass Spectrometry | 2020 |